|
MechanismTNF-α inhibitors |
Active Org.- |
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study
This is a prospective, randomized, double-blind, parallel group, multicentre global phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of BOW015 (infliximab-EPIRUS) compared to Remicade in subjects with active Rheumatoid Arthritis (RA) despite Methotrexate (MTX) therapy.
100 Clinical Results associated with Epirus Biopharmaceuticals (Switzerland) GmbH
0 Patents (Medical) associated with Epirus Biopharmaceuticals (Switzerland) GmbH
100 Deals associated with Epirus Biopharmaceuticals (Switzerland) GmbH
100 Translational Medicine associated with Epirus Biopharmaceuticals (Switzerland) GmbH